{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:30:47Z","timestamp":1790314247371,"version":"4.1.0"},"reference-count":37,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"argenx Japan K.K"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.1080\/14712598.2025.2490063","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T03:37:26Z","timestamp":1744169846000},"page":"543-550","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9576-8789","authenticated-orcid":false,"given":"Hirofumi","family":"Teranishi","sequence":"first","affiliation":[{"name":"Argenx Japan K.K","place":["Minato-ku, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4790-7301","authenticated-orcid":false,"given":"Koichi","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Argenx Japan K.K","place":["Minato-ku, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumiko","family":"Kanzaki","sequence":"additional","affiliation":[{"name":"Argenx Japan K.K","place":["Minato-ku, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyo","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Argenx Japan K.K","place":["Minato-ku, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-5935","authenticated-orcid":false,"given":"Daisuke","family":"Harada","sequence":"additional","affiliation":[{"name":"Argenx Japan K.K","place":["Minato-ku, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0756-3"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00297-0"},{"key":"e_1_3_8_5_1","unstructured":"Matsui M Ogino E Izumi Y et al. Validations of the adequacy of diagnosis criteria severity classification and guidelines based on neuro-immune disease evidence and the patient\u2019s QOL. Health labour sciences research grant 2018. (in Japanese) [cited 2025 Jan 29]. Available from: https:\/\/mhlw-grants.niph.go.jp\/project\/27179"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12731"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.003"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108327"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.44"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.11.005"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1313944110"},{"key":"e_1_3_8_13_1","volume-title":"Practical guideline for myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) 2022","author":"Societas Neurologica Japonica","year":"2022","unstructured":"Societas Neurologica Japonica. Practical guideline for myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) 2022. Tokyo: Nankodo; 2022."},{"issue":"7","key":"e_1_3_8_14_1","first-page":"465","article-title":"Neuroimmunological disorders \u2013 the latest scientific findings of basic and clinical researches \u2013 immunological muscle disorder, myasthenia gravis \u2013 autoantibodies and clinical condition of myasthenia gravis","volume":"73","author":"Shima T","year":"2015","unstructured":"Shima T, Motomura M. Neuroimmunological disorders \u2013 the latest scientific findings of basic and clinical researches \u2013 immunological muscle disorder, myasthenia gravis \u2013 autoantibodies and clinical condition of myasthenia gravis. Nippon Rinsho Tokyo. 2015;73(extra number 7):465\u2013471. Japanese.","journal-title":"Nippon Rinsho Tokyo"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25397"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24213"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23398"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013278"},{"key":"e_1_3_8_20_1","unstructured":"argenx US Inc. Prescribing information of VYVGART. 2024 Aug [cited 2025 Jan 29]. Available from: https:\/\/argenx.com\/product\/vyvgart-prescribing-information.pdf"},{"key":"e_1_3_8_21_1","unstructured":"argenx Japan K.K. Prescribing information of VYVGART. 2024 Mar. (Japanese). [cited 2025 Jan 29]. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/113014_6399430A1029_1_07"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2136167"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00498-8"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.892534"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25680"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20782"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444"},{"key":"e_1_3_8_30_1","unstructured":"Japan Pharmaceutical Manufacturers Association. Pharmaceutical administration and regulations in Japan chapter 4. Post-marketing surveillance of drugs. 2020 [cited 2025 Jan 29]. Available from: https:\/\/www.jpma.or.jp\/english\/about\/parj\/eki4g6000000784o-att\/2020e_ch04.pdf"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.7.1487"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.1.16"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200276"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330519"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9586"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863095"},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2490063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:18:54Z","timestamp":1751876334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2490063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,4]]}},"alternative-id":["10.1080\/14712598.2025.2490063"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2490063","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}